Evidence map›Paper›PMID 30918427›Full record

ArticleWorld journal of gastroenterology2019

Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.

Jong Lyul Lee, Seon Ae Roh, Chan Wook Kim, Yi Hong Kwon, Ye Jin Ha, Seon-Kyu Kim, Seon-Young Kim, Dong-Hyung Cho, Yong Sung Kim, Jin Cheon Kim

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jong Lyul LeeDepartment of Surgery, University of Ulsan College of Medicine, Seoul 05505, South Korea.
Seon Ae RohInstitute of Innovative Cancer Research, Asan Medical Center, Seoul 05505, South Korea.
Chan Wook KimDepartment of Surgery, University of Ulsan College of Medicine, Seoul 05505, South Korea.
Yi Hong KwonInstitute of Innovative Cancer Research, Asan Medical Center, Seoul 05505, South Korea.
Ye Jin HaInstitute of Innovative Cancer Research, Asan Medical Center, Seoul 05505, South Korea.
Seon-Kyu KimMedical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea.
Seon-Young KimMedical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea.
Dong-Hyung ChoSchool of Life Sciences, Kyungpook National University 80 Daehak-ro, Daegu 41566, South Korea.
Yong Sung KimMedical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea.
Jin Cheon KimDepartment of Surgery, University of Ulsan College of Medicine, Seoul 05505, South Korea.
University of Ulsan · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenomic profiling of tumors has contributed to the understanding of colorectal cancer (CRC), facilitating diagnosis, prognosis and selection of treatments, including targeted regimens. A report suggested that a 19-gene-based risk classifier (TCA19) was a prognostic tool for patients with stage III CRC. The survival outcomes in patients with stage IV CRC are still poor and appropriate selection of targeted therapies and immunotherapies is challenging.

aimTo assess clinical implication of TCA19 in patients with stage IV CRC, and to identify TCA19 with involvement in immune-oncology.

methodsA retrospective review of the medical records of 60 patients with stage IV CRC was conducted, assessing clinicopathological variables and progression-free survival (PFS). TCA19 gene expression was determined by quantitative polymerase chain reaction (qPCR) in matched normal and tumor tissues taken from the study cohort. Expression of potential immune-oncology regulatory proteins and targets was examined by immunohistochemistry (IHC), western blot, immunofluorescence staining in tissues from a validation cohort of 10 patients, and in CRC cell lines co-cultured with monocyte

resultsIn the patients with TCA19 score higher than the median, the PFS rates of eight patients who received the targeted regimens were significantly higher than the PFS rates of four patients who received 5-fluorouracil-based regimen (

conclusionThe TCA19 score might be prognostic for target-regimen-specific PFS in stage IV CRC. Down-regulation of SLAMF7 and up-regulation of TREM1 occur in primary and metastatic tumor tissues.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCell Line, TumorCoculture TechniquesColorectal NeoplasmsDown-RegulationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingBiomarkers, TumorSignaling Lymphocytic Activation Molecule FamilySLAMF7 protein, humanTREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1Colorectal cancerImmunotherapyPrognosisSignaling lymphocytic activation molecule family, member 7Triggering receptor expressed on myeloid cells 1

Identifiers

PMID30918427
PMCPMC6429345
OpenAlexW2922717474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.